B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity
This post hoc analysis of the randomized, placebo-controlled N-MOmentum study (NCT02200770) of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD) evaluated relationships between circulating B-cell subsets and aquaporin-4 immunoglobulin G (AQP4-lgG) titers and attacks. Among participants receiving placebo, CD20<sup>+</sup> and CD27<sup>+</sup> B-cell counts were modestly increased from the pre-attack visit to attack; plasmablast/plasma cell gene signature was increased from baseline to the pre-attack visit (p = 0.016) and from baseline to attack (p = 0.009). With inebilizumab treatment, B-cell subset counts decreased and did not increase with attacks. No difference in change of AQP4-IgG titers from baseline to time of attack was observed.
Authors
- Jeffrey L. Bennett (ORCID: https://orcid.org/0000-0002-3346-1394)
- Bruce Cree (ORCID: https://orcid.org/0000-0001-7689-2533)
- William A. Rees (ORCID: https://orcid.org/0000-0003-1857-8364)
- Sarosh R. Irani (ORCID: https://orcid.org/0000-0002-7667-9748)
- Friedemann Paul (ORCID: https://orcid.org/0000-0002-6378-0070)
- Kristina R. Patterson (ORCID: https://orcid.org/0000-0002-6421-6869)
- Michele Gunsior (ORCID: https://orcid.org/0000-0002-6086-5968)
- Sean Joseph Pittock (ORCID: https://orcid.org/0000-0002-6140-5584)
- Ho Jin Kim (ORCID: https://orcid.org/0000-0002-8672-8419)
- Michael A. Smith (ORCID: https://orcid.org/0009-0005-3694-3187)
- Nanette Mittereder (ORCID: https://orcid.org/0000-0001-7468-4095)
- Daniel Cimbora (ORCID: https://orcid.org/0000-0001-9835-1527)
- Kevin C. O'Connor
Institutions
- Amgen (United States) (US)
- Mayo Clinic (US)
- University of California, San Francisco (US)
- Max Delbrück Center (DE)
- Jacksonville College (US)
- Yale University (US)
- University of Oxford (GB)
- Horizon Therapeutics (United States) (US)
- National Cancer Center (KR)
- Mayo Clinic in Florida (US)
- University of Colorado Anschutz Medical Campus (US)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1002/acn3.52171
- Citations
- 11
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.67
Funders
- Amgen
- AstraZeneca
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Guthy-Jackson Charitable Foundation
- CSL Behring
- Handok
- Wellcome Trust
- TG Therapeutics
- Atara Biotherapeutics
- Argenx
- Horizon Therapeutics
- National Institute for Health and Care Research
- National Research Foundation
- Deutsche Forschungsgemeinschaft
- National Research Foundation of Korea
- Eisai
- Daewoong Pharmaceutical Company
- Astellas Pharma
- Mitsubishi Tanabe Pharma Corporation
- Genentech
- EMD Serono
- Sanofi Genzyme
- Medical Research Council